Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (January 2021)
26 slides from Genocea Biosciences's investor presentation, Jan 4, 2021
Slide 1: Better personalized cancer immunotherapies through better neoantigen targeting
Better personalized cancer immunotherapies through better neoantigen targeting January 2021
Slide 2: Forward-looking statements
2 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or a
Slide 3: Genocea at a glance
3 Genocea at a glance TARGETS MATTER GEN-009 Neoantigen vaccine Longer term efficacy in combination with checkpoint inhibitor Q2 2021 Monotherapy efficacy in checkpoint-resistant patients Late Q4 2021/Q1 2022 GEN-011 Neoantigen cell therapyDifferentiated clinical-stage immunotherapies Revolutionary
Slide 4: ATLAS: harnessing each patient's immune system for optimal antigen selection
4 ATLAS: harnessing each patient’s immune system for optimal antigen selection Only ATLAS can identify: - All stimulatory antigens in a patient’s tumor - InhibigensTM – antigens of CD8+ and/or CD4+ T cells that suppress anti-tumor responses Available fixed tumor sample NGS analysis Bacterial vectors
Slide 5: Inhibigen identification and exclusion is critical to ensure therapeutic efficacy
5 Inhibigen identification and exclusion is critical to ensure therapeutic efficacy 1. Therapeutic mouse vaccination with a pool of ATLAS-identified Inhibigens drives tumor hyperprogression 2. The presence of Inhibigens in an otherwise protective mouse vaccine completely abrogates protection 3. Chec
Slide 6: ATLAS: enabling better products through superior antigen selection
6 ATLAS: enabling better products through superior antigen selection
Slide 7: GEN-009 Neoantigen Vaccine
7 GEN-009 Neoantigen Vaccine Unprecedented immune responses; Emerging clinical efficacy
Slide 8: GEN-009-101 trial design
GEN-009-101 trial design Part A • Vaccine monotherapy in patients with no evidence of disease • Multiple tumor types with CPI approval • Objectives: safety, immunogenicity, recurrence-free survival • Status: all patients in long-term follow-up Part B • Combination of GEN-009 and standard-of-care PD-
Slide 9: Strong immune responses and recurrence-free survival in Part A
9 1 Sahin, et al., Nature 2017 (N=8); Ott, et al., Nature 2017 (N=8); Gritstone ESMO Immuno-Oncology Congress Presentation 2019 • Results shown represent highest proportion of neoantigen-specific responses in peer publications and presentations Immune response frequency % neoantigens with immune res
Slide 10: In Part B, GEN-009 is being studied in two distinct patient groups
10 In Part B, GEN-009 is being studied in two distinct patient groups Biopsy +/- prior therapy SOC and GEN-009 manufacture Enroll 1. Checkpoint-sensitive / controlled GEN-009 dosing 2. Checkpoint-resistant GEN-009 dosingProgression and salvage treatment SOC Therapy Melanoma: nivo monotherapy or nivo
Slide 11: Part B design enables assessment of vaccine-specific contribution
11 Part B design enables assessment of vaccine-specific contribution to clinical responses Each patient can serve as own control
Slide 12: Compelling signal of response in checkpoint-sensitive patients
12 Compelling signal of response in checkpoint-sensitive patients Overall responses 2/9 (22%) with CR 4/9 (67%) with PR 2/9 (22%) with SD 7/9 (78%) progression-free GEN-009 responses 1 CR and 2 PR of 7 evaluable
Slide 13: Early evidence of stabilization in checkpoint-resistant patients
13 Early evidence of stabilization in checkpoint-resistant patients Investigator iRECIST read after GEN-009 5/7 disease control 1 patient with possible pseudo-progression
Slide 14: GEN-009 continues to demonstrate unparalleled immune responses
14 GEN-009 continues to demonstrate unparalleled immune responses 0 100 200 300 400 500 600 700 800 900 screening D50 Cy to ki ne S FU /2 0, 00 0 PB M C IFN-gamma TNF-alpha PBMC IV S Re su lts (N = 1 0 ) ~35,000/million 0 100 200 300 400 500 600 700 800 900 screening D50 Cy to ki ne S FU /2 0, 00 0
Slide 15: GEN-009: Delivering on the promise of neoantigen therapies
15 Compelling early signals persist with longer follow-up Clear anti-tumor activity “Targets matter” Highly differentiated immunogenicity results Powerful readthrough to GEN-011 ATLAS enables unique breadth and specificity GEN-009: Delivering on the promise of neoantigen therapies
Slide 16: GEN-011 Neoantigen T cell Therapy
16 GEN-011 Neoantigen T cell Therapy Potential best-in-class solid tumor adoptive T cell therapy
Slide 17: TIL therapy: current gold standard for solid tumor cell therapy
17 TIL therapy Current gold standard for solid tumor cell therapy 1. Linette et al., Blood (2013) 2. Goff et al., JCO (2016) 3. Sarnaik et al., ASCO Annual Meeting (2019) 4. Jazaeri et al., ASCO Annual Meeting (2019) CAR-T Unproven in solid tumors TCR-transduced (TCR-T) Limited clinical validation H
Slide 18: GEN-011: a new category of solid tumor cell therapy
18 GEN-011 A new category of solid tumor cell therapy: Neoantigen-targeted Peripheral T cells (NPTs) Peripheral blood (leukopak) Up to 30 neoantigens Neoantigen-specific cell expansion in fully closed single-use vessels GEN-011 NPTs: Non-engineered, neoantigen-specific
Slide 19: GEN-011 overcomes limitations of other solid tumor cell therapy approaches
19 GEN-011 overcomes limitations of other solid tumor cell therapy approaches
Slide 20: GEN-011 delivers billions of NPTs
20 GEN-011 delivers billions of NPTs that are: Highly neoantigen-specific 96% Antigen Specific A ct iv a tio n M a rk er 2 Activation Marker 1 16:1 8:1 4:1 2:1 1:1 0.5:1 0 20 40 60 80 100 Effector:Target ratio % C yt ot ox ic ity Specific Neoantigens Unpulsed Control Powerfully cytolytic against the
Slide 21: GEN-011 provides unparalleled breadth of neoantigen coverage
21 89% GEN-011 NPTs are specific for 89% of all intended neoantigen targets* *Mean across development runs with cancer patient material Recent selected TIL data show successful amplification to only 4% of antigens included in the process1 Recent conventional TIL data show responses to an average of
Slide 22: Robust and rapidly scalable manufacturing process
22 Robust and rapidly scalable manufacturing process with fully closed single-use technology Peripheral blood (leukopak) Up to 30 verified neoantigens Expansion of neoantigen-specific cells in fully closed single-use GRex vessels T cells Phenotypic cell sort Monocyte-derived dendritic cells Peripher
Slide 23: TITAN trial: GEN-011 in patients with CPI-resistant solid tumors
23 TITAN trial: GEN-011 in patients with CPI–resistant solid tumors Trial Objectives Accruing patients Cohort A Multiple low dose (up to 12 patients) • No lymphodepletion • Low dose IL-2 • Safety • Clinical activity • ORR • DOR • GEN-011 proliferation and persistence • Tumor T cell penetration Trial
Slide 24: GEN-011: Transforming neoantigen T cell therapy for solid tumors
24 CD8+ and CD4+ T cells targeting up to 30 neoantigens Robust and rapidly scalable manufacturing process Peripheral blood enabling greater accessibility, activity and durability GEN-011: Transforming neoantigen T cell therapy for solid tumors
Slide 25: Genocea at a glance
25 Genocea at a glance TARGETS MATTER GEN-009 Neoantigen vaccine Longer term efficacy in combination with checkpoint inhibitor Q2 2021 Monotherapy efficacy in checkpoint-resistant patients Late Q4 2021/Q1 2022 GEN-011 Neoantigen cell therapyDifferentiated clinical-stage immunotherapies Revolutionary
Slide 26: Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 www.genocea.com
26 NASDAQ: GNCA 100 Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 www.genocea.com
Genocea Biosciences — Investor Presentation (January 2021) on 6ix